Literature DB >> 22834451

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.

Alkomiet Hasan1, Peter Falkai, Thomas Wobrock, Jeffrey Lieberman, Birte Glenthoj, Wagner F Gattaz, Florence Thibaut, Hans-Jürgen Möller.   

Abstract

These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry Guidelines for Biological Treatment of Schizophrenia published in 2005. For this 2012 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations that are clinically and scientifically meaningful and these guidelines are intended to be used by all physicians diagnosing and treating people suffering from schizophrenia. Based on the first version of these guidelines, a systematic review of the MEDLINE/PUBMED database and the Cochrane Library, in addition to data extraction from national treatment guidelines, has been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into six levels of evidence (A-F; Bandelow et al. 2008b, World J Biol Psychiatry 9:242). This first part of the updated guidelines covers the general descriptions of antipsychotics and their side effects, the biological treatment of acute schizophrenia and the management of treatment-resistant schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22834451     DOI: 10.3109/15622975.2012.696143

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  145 in total

Review 1.  Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review.

Authors:  Selene R T Veerman; Peter F J Schulte; Lieuwe de Haan
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

2.  Does Non-Adherence Increase Treatment Costs in Schizophrenia?

Authors:  Mark Pennington; Paul McCrone
Journal:  Pharmacoeconomics       Date:  2018-08       Impact factor: 4.981

3.  Effectiveness of long-acting antipsychotics in clinical practice : 1. A retrospective, 18-month follow up and comparison between paliperidone palmitate, risperidone long-acting injection and zuclopenthixol decanoate.

Authors:  Matthew Cordiner; Polash Shajahan; Sarah McAvoy; Muhammad Bashir; Mark Taylor
Journal:  Ther Adv Psychopharmacol       Date:  2016-02

4.  Sodium nitroprusside is effective in preventing and/or reversing the development of schizophrenia-related behaviors in an animal model: The SHR strain.

Authors:  Mariana C Diana; Fernanda F Peres; Veronica Justi; Rodrigo A Bressan; Acioly L T Lacerda; José Alexandre Crippa; Jaime E C Hallak; Vanesssa Costhek Abilio
Journal:  CNS Neurosci Ther       Date:  2018-04-14       Impact factor: 5.243

Review 5.  Transcranial direct current stimulation in psychiatric disorders.

Authors:  Gabriel Tortella; Roberta Casati; Luana V M Aparicio; Antonio Mantovani; Natasha Senço; Giordano D'Urso; Jerome Brunelin; Fabiana Guarienti; Priscila Mara Lorencini Selingardi; Débora Muszkat; Bernardo de Sampaio Pereira Junior; Leandro Valiengo; Adriano H Moffa; Marcel Simis; Lucas Borrione; André R Brunoni
Journal:  World J Psychiatry       Date:  2015-03-22

6.  Epigenetic mechanisms in the pathophysiology of psychotic disorders.

Authors:  W Brad Ruzicka
Journal:  Harv Rev Psychiatry       Date:  2015 May-Jun       Impact factor: 3.732

Review 7.  Switching and augmentation strategies for antipsychotic medications in acute-phase schizophrenia: latest evidence and place in therapy.

Authors:  Kotaro Hatta; Naoya Sugiyama; Hiroto Ito
Journal:  Ther Adv Psychopharmacol       Date:  2018-01-29

Review 8.  Psychosis.

Authors:  David B Arciniegas
Journal:  Continuum (Minneap Minn)       Date:  2015-06

Review 9.  Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders.

Authors:  Kenji Hashimoto; Berend Malchow; Peter Falkai; Andrea Schmitt
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-03-01       Impact factor: 5.270

10.  Driving skills in unmedicated first- and recurrent-episode schizophrenic patients.

Authors:  Felix M Segmiller; Verena Buschert; Gerd Laux; N Nedopil; Ulrich Palm; Katharina Furjanic; Peter Zwanzger; Alexander Brunnauer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-10-25       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.